Skip to nav Skip to content

Clinical Trial Search

306 Clinical Trials Found

Clinical Trial 21997

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
Disease Site: Other Skin
PI: Eroglu, Zeynep

Clinical Trial 22002

A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS
Disease Site: Any Site, Liver, Lung, Other Digestive Organ, Pancreas, Small Intestine, Stomach
PI: Kim, Dae Won

Clinical Trial 21707

A Proof of Concept Study of TBio-4101 (an Autologous selected and expanded tumor infiltrating lymphocyte [TIL] therapy) Using Short-Term Cultured, Selected Autologous TIL following a Lymphodepleting Chemotherapy Regimen and Followed by IL-2 for Patients with Relapsed or Refractory Solid Tumors (Phase 1)
Disease Site: Colon, Melanoma, skin, Rectum
PI: Sarnaik, Amod

Clinical Trial 22100

Disease Site: Multiple Myeloma
PI: Grajales-Cruz, Ariel

Clinical Trial 22134

AbatacepT foR ImmUne checkpoint inhibitor associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Compared to Placebo in Hospitalized Participants with Immune Checkpoint Inhibitor Associated Myocarditis
Disease Site: Other
PI: Alomar, Mohammed

Clinical Trial 22254

A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
Disease Site: Urinary Bladder
PI: Jain, Rohit

Clinical Trial 22305

Disease Site: Breast, Lung, Other Respiratory and Intrathoracic Organs
PI: Soyano Muller, Aixa

Clinical Trial 21415

Disease Site: Other Hematopoietic
PI: Kuykendall, Andrew

Clinical Trial 21634

A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
Disease Site: Non-Hodgkin's Lymphoma
PI: Bello, Celeste

Clinical Trial 22080

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
PI: Chavez, Julio

Clinical Trial 90038

Disease Site: Other Hematopoietic
PI: Deutsch, Yehuda

Clinical Trial 90037

Disease Site: Non-Hodgkin's Lymphoma
PI: Vargas Madueno, Fernando